Medizinisches Versorgungszentrum Offenburg Weingartenstraße | Dr. Link (Ärztlicher Direktor) Publikationen

Publikationen

A list of published papers:

  1. Immunogenicity of synthetic oligopeptides corresponding to epitopes of Friends murine leukemia virus glycoprotein covalently linked to lipopeptides.
    Ralph Link, T. Böltz et al.
    Immunobiol.  178; 64.

  2. Histopathological Studies on the local reactions induced by complete Freund´s Adjuvant (CFA), bacterial Lipopolysaccharide (LPS), and synthetic Lipopeptide (P3C) Conjugates.
    Frank Wiedemann, Ralph Link et al.
    Journal of Pathology, Vol. 164:265-271(1991)

  3. Immunogenität synthetischer F-MuLV- und HIV-Oligopeptid-Lipopeptid-Konjugate in BALB/c- und STU-Mäusen.
    W. Bessler, R. Link et al.
    Abstract, 2. Deutscher AIDS-Kongress, Berlin, FRG.

  4. Safety and Tolerability of Peginterferon Alpha-2A (40KD)(PEGASYS) Monotherapy and combination Therapy with Ribavirin (COPEGUS) in Patients with chronic Hepatitis C: Results of a German, Multicenter open-label  trial
    B. Möller,..Ralph Link et al.
    Journal of Viral Hepatitis, Volume 14, Number 11, November 2007, pp788-796(9)

  5. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy
    Wulf O.Böcher,..Ralph Link et al.
    Liver International 2006:26; 319-325

  6. Comparison of a 24-week standard combination therapy with PEG-IFN alfa-2a/Ribavirin with a 12-week monotherapy with PEG-IFN alfa-2a followed by a 12 week standard combination with PEG-IFN alfa-2a/Ribavirin in Hepatitis C infected patients with genotyp 2 or 3.
    Kallinowski Birgit,….Link Ralph et al.
    Presented at the 57 Annual Meeting of the American Ass. for the Study of Liver Diseases 2006 October 27-31; Boston;Massachusetts; USA

  7. K-light chain amyloidosis of the liver, a rare cause of liver enzyme elevation
    J.P. Borde, R. Link, W.B. Offensperger
    Dtsch Med Wochenschrift 2008;133;116-1120

  8. Estimating the Likelihood of Sustained Virological Response in Chronic Hepatitis C (CHC) Therapy
    Mauss S., Hueppe D.,….Link R. et al.
    Presented at the 43 Annual Meeting of the European Ass. for the Study of Liver (EASL) 2008 April 23-27; Milan, Italy
    Journal of Viral Hepatitis, 2010 / j.1365-2893

  9. Efficacy and Tolerability of Peginterferon alpha-2a or  - 2b plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Germany: The PRACTICE Study
    Witthoeft T, Hueppe D., ….Link R. et al.
    Presented at the 43 Annual Meeting of the European Ass. for the Study of Liver (EASL) 2008 April 23-27; Milan, Italy

  10. Comparison of the efficacy of peginterferon alfa-2a and -2b plus ribavirin in the treatment of chronic hepatitis C patients in daily routine: results from Practice
    Witthoeft Thomas, …Link Ralph et al.
    AASLD Poster 2010
    EASL-Abstract 2008,  Mailand

  11. Effektivität und Sicherheit von Escitalopram zur Prävention PEG-IFN-alpha assoziierter Depressionen bei Patienten mit chronischer Hepatitis C (CIPPAD-Studie)
    Schaefer, M.; Sarkar, R.;…Link, R.: et al.   
    Hepatology 2008;48(4):423A

  12. Daily consensus interferon versus peg-interferon alfa2b with weight based ribavirin in treatment-naive patients with chronic hepatitis C serotyp-1     
    M. Schuchmann, H.F. Löhr, R. Link, et al.        
    AASLD 2007

  13. Daily consensus interferon versus peg-interferon alfa2b with weight based or 800 mg ribavirin in treatment-naive patients with chronic hepatitis C genotypes 2 or 3     
    F. Rahman; M. Schuchmann; H. F. Löhr; R. Link; P. Buggisch; et al.     
    ASLD 2007

  14. consensus interferon/ribavirin versus peg-interferon alfa2b/ribavirin in treatment-naive Daily patients with chronic hepatitis C and serotype-2 or –3: Interim results from the PACT-trial              
    W.O. Böcher, M. Fuchs, P. Buggisch, S. Kaiser, R. Link, et al.              
    AASLD 2007

  15. longterm benefits of sustained  virological response (SVR) in patients with chronic hepatitis C (CHC) virus infection: The German „LOTOS STUDY“
    Reimer. J., ……   Link. R., et al.  
    DDW 2011 Chikago; Posternummer 6795

  16. Kostenevaluation der ärztlichen Leistung einer Behandlung der cHCV mit Peginterferon alfa-2a und Ribavirin als Beitrag zur Qualitätssicherung im Gesundheitswesen.  
    S.Rossol, M.Schuchmann,…  R.Link, et al.

  17.  PEG-Interferon-alfa2a/ribavirin  - phlebotomy in HCV GT 1patients – final results oft he KAPRI trial.
    Erhardt, B.Möller,… R. Link, et. al.

  18. Pathological glucose tolerance and treated hypertension identify HCV-patients wit h negative prognostic parameters for SVR.
    E. Jaeckel, E. Zehnter, T. Lutz,… R. Link, et al.

  19. Confirmation of high SVR rates after shortening duration of treatment with Peginterferon alfa-2a (PEG) and Ribavarin (RBV) in Chronic Hepatitis C (CHC) Patient with RVR In Real Life.
    Stefan Mauss, Ralph Link, et al.
    eingereicht AASLD San Franzisco 2011

  20. Pharmaeconomic Evaluation of chronic HCV Treatment with Peginterferon alfa-2a/Ribavirin-real life setting in a large German cohort of 1147 patients.
    S. Rossol, M. Schuchmann, S. Mauss...R. Link,  et al.
    eingereicht AASLD San Franzisco 2011

  21. The role of ferritin as aresponse marker for antiviral treatment of chronic Hepatitis C patients wit Peginterferon alfa-2a (PegIFN) and Ribavirin (RBV).
    KLass D.M., Zizer E., Link R., …, et al.
    eingereicht AASLD San Franzisco 2011

  22. The role of weight loss (WL) as on treatment predictive Factor for SVR in the treatment of chronic Hepatitis C (CHC) patients with Peginterferon alfa-2a (PEG) and Ribavirin.
    Thomas Witthoeft, Klaus Boeker,…, Ralph Link, et al.      
    eingereicht AASLD San Franzisco 2011

  23. Predictive factors for nonresponse in genotype  2/3 infected chronic hepatitis C patients treated with Peginterferon alpha-2a and Ribavirin in real life setting
    J. Petersen, T. Lutz, R. Link, et al…………….
    EASL 2012 Abstract A-455-0022-00894, Barcelona, Spain
    DDW 2012

  24. Viral response at week 2 as a predictive factor for RVR in chronic HCV Genotyp 1 Infection treated with Peginterferon-alpha-2a and Ribavirin
    S. Mauss; T.Lutz; K.Boeker; R. Link; et al……………….
    EASL 2012 Abstract A-455-0022-0084, Barcelona, Spain
    DDW 2012

  25. Early markers of metabolic syndrome are associated with distinct HCV genotypes, while abnormal glucose tolerance substantially decreases  the likelyhood of SVR
    E. Jaeckel, E. Zehnter, T. Lutz, A.Carlebach, R. Link et.al………….
    EASL 2012 Abstract, Barcelona, Spain

  26. Effects of pre-treatment with bezafibrate followerd by standard of care in treatment-naive patients with chronic hepatitis C genotyp 1 infection and elevated GGT levels.
    A.Böhig, V.Weich, ………Ralph Link; et al…
    WORDS  Abstract 350

  27. Starke Assoziation von Markern des metabolischen Syndroms miz HCV Genotyp 1,4,5 und schlechtes Therapieansprechen bei Patienten mit gestörter Glucosetoleranz.
    E. Jaeckel, E. Zehnter, R. Link; et al.
    EASL 2012 Abstract

  28. Patient Adherence:  The influence of non-virological factors  in a real world setting
    T. Witthöft,  R. Link; et al.
    DGVS  2012

  29. Clinical Presentation of Chronic Liver Disease in Germany:  Role of Etiology, Age and Gender,
    A. Tromm, J. Petersen, P. Buggisch, S. Holm, R. Link; et al.
    DGVS  2012

  30. Factors associated with rapid virological response (RVR) in the treatment of chronic hepatitis C (cHC) with Peginterferon alfa-2a (PEG) and Ribavirin (RBV) in patients with and without opioid substitution treatment (OST)
    Jens Reimer; Bernd Weber;... Ralph Link; et al.     
    Abstract  AASLD 2012, Boston, Massachusetts (1420283)

  31. Escitalopram fort he pevention of peginterferon alpha-2a- and ribavirin-associated depression in HCV-infected patients
    Martin Schaefer, MD;…Ralph Link, MD; et al.
    Abstract JAMA 10-7938

  32. Epidemiologie, Behandlungsergebnisse und Kosten der Behandlung chronischer HCV-Patienten in Deutschland – Ergebnisse einer großen Multicenter Studie.
    Rossol S; Stahmeyer J.T.; Bert F; Mauss S; Link R; et al.     
    Konferenz Viszeralmedizin 2013 Abstract A-592-0004-00323

  33. Gründe zur Ablehnung einer Hepatitis C Therapie vor dem Hintergrund neuer  Therapieoptionen.
    Mauss S.; Stoehr A.; Schober A.; Holm S.; Beoker K.H.W.; Link R.; et al.
    Z.Gastro 44(8), 797 Abstr. P275 (2006), Kongress Viszeralmedizin 2013 (DGVS)

  34. Prädiktive Baseline Faktoren bei Patienten mit Zirrhose für den Therapieerfolg einer dualen Therapie mit Peginterferon alfa-2a (PEG) plus Ribavirin (RBV), was zählt?
    Hueppe D.; Mauss S.; ……Link R.; Moog G.; et al.
    eingereicht Kongress Viszeralmedizin 2013 (DGVS)

  35. Real world efficacy and safety of 28 week-therapy containing boceprevir, peginterferon alpha-2a and ribavirin in treatment-naive patients: first SVR data of German non-interventional PAN Study
    Peter Buggisch, Andreas Schober;…………Ralph Link…et al.
    AASLD-The Liver Meeting 2013, Washington, DC

  36. 24 week treatment of  former relapse, HCV genotyp 1 infected patients with telaprevir in combination with peginterferon alpha 2a/ribavirin-experiences under real life condituions
    Klaus H. Boeker; Ralph Link et al.
    AASLD-The Liver Meeting 2013, Washington, DC

  37. Baseline characteristics and treatment response of HCV genotyp 1 patients with previous null response that are retreated with  TVR or BOC triple therapy  in real world setting
    Wolf P.Hofmann, Stefan Mauss;…Ralph Link;…………et al.
    AASLD-The Liver Meeting 2013, Washington, DC

  38. Patient Adherence: the Influence of Non-virological Factors in a Real word Setting
    Thomas Witthoeft, Ralph Link, et al.     
    APASL 2013 abstract

  39. Quality of Life Profiles in Patients in Contact with the Hepatitis C Virus
    Reimer J; Hueppe D;………Link R;…et al.
    3rd Intern. Symposium on Hepatitis Care in Substance Users (INHSU 2013); Munich

  40. Baseline Characteristics and Treatment Response of HCV Genotyp 1 Patients with Previous Null Response That Are Retreated with TVR or BOC  Triple Therapy in Real World Setting 
    Hofmann WP;Mauss S; Baumgarten A; Boeker KH; Link R; ..et al.
    AASLD-The Liver Meeting 2013, Washington, DC, USA

  41. Overtreatment of Patients with chronic Hepatitis C (cHC) Genotyp 2/3 with low baseline viral load and RVR: Experiences ia a real world setting
    B.Heinrich; St. Wiegand; J.Petersen; H.Hinrichsen; Ralph Link; et al.
    AASLD-The Liver Meeting 2013, Washington, DC, USA

  42. Performance and value of IFN-Lambda 3 and IFN-Lambda 4 Genotyping in Patients with chronic Hepatitis C (cHC) Genotype 2/3 in a real world setting
    St. Wiegand; B. Heinrich; S.Susser; …; Ralph Link;.. et al.
    AASLD-The Liver Meeting 2013, Washington, DC, USA

  43. 24 Week Re-treatment with Telaprevir-Triple Therapy in Patients with HCV-Genotype 1 who had Relapsed after Peginterferon/Ribavirin Treatment.  
    Boeker KH; Link Ralph; et al.        
    AASLD-The Liver Meeting 2013, Washington, DC, USA

  44. Safety analysis of Endoscopist-Directed Sedation.  A prospective, national multicenter study of 24.441 patients in German outpatient practices  
    Andreas Sieg, Ralph Link in bng-Study-Group, Sebastian Beck; et al.  
    Gastroenterology, in process

  45. Smoking does not negatively influence Interferon-based antiviral Therapy in Treatment naive,  HCV Genotype 1 infected Patients  
    Tim Zimmermann; Klaus.H.W. Boecker; Andreas Schober; … Ralph Link;…et al.   
    EASL 2014, Abstract eingereicht

  46. Baseline characteristics and treatment efficacy of telaprevir in combination with peginterferon alfa-2a and ribavirin in 253 HCV genotype 1 nonresponder patients in a real-world setting.
    W.P. Hofmann; S.Mauss;A.Baumgarten;K.H.W. Boecker; R. Link et al.
    EASL 2014, Abstract London

  47. Triple therapy with boceprevir (BOC) under daily conditions: Is it possible to achieve SVR rates comparable to pivotal trials?
    Peter Buggisch; Andreas Schober; …Ralph Link;… et al.   

    EASL 2014, Abstract London

  48. Adverse Events and co-medication: a comparison between dual and triple combination therapies in genotype 1 patients with chronic  hepatitis C
    Eckart Schott; Andreas Schober; Ralph Link; et al.
    EASL 2014, Abstract London

  49. Sustained virological response (SVR) in HCV treatment-experienced patients after triple therapy with boceprevir (BOC) plus peginterferon alfa-2a / ribavirin in a real-life setting. 
    Klaus H.W. Boecker; Ralph Link, Axel Baumgarten; et al.  
    EASL 2014, London

  50. Non-virological factors predicting patient adherence during antiviral treatment of genotyp 1/4  infection in real world: role of gender and age       
    Thomas Witthoeft; Ralph Link; Stefan Christensen; et al.  
    Hepatology, Volume 58, Number 4; AASLD Abstract 2013 in Washington

  51. Baseline characteristics and treatment  response of HCV genotype 1 patients with previous null response that are retreated with TVR or BOC triple therapy in real world setting 
    Wolf P. Hofmann; Stefan Mauss; Axel Baumgarten; Klaus H. Boeker; Ralph Link; et al.
    Hepatology, Volume 58, Number 4;   AASLD Abstract 2013 in Washington 

  52. 24 week treatment of former relapse, HCV genotype 1 infected patients with telaprevir in combination with peginterferon alfa 2a/ribavirin – experiences under real life conditions
    Klaus H. Boeker; Ralph Link; et al.   
    Hepatology, Volume 58, Number 4;   AASLD Abstract 2013 in Washington

  53. Trearment of naiv patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: Relevance for the new era of DAA  
    Benjamin Heidrich; Steffen B. Wiegand;…Ralph Link; Uwe Naumann; et al.  
    PLOS ONE   October 2014 / Volume 9 / Issue 10 / e108751

  54. Respiratory Complications in Outpatient Endoscopy with Endoscopist-Directed Sedation.
    Kilian Friedrich; Sabine G. Scholl;… Ralph Link in bng-Study-Group; Andreas Sieg et al.    
    J. Gastrointestin Liver Dis, September 2014; Vol. 23 No 3.

  55. Treatment of Naive Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting;  
    Relevance for the New Era of DAA  
    Benjamin Heidrich; Steffen B. Wiegand;…Ralph Link; …Markus Cornberg, et al.   
    PLOS ONE   October 2014 / Volume 9 / Issue 10 / e108751

  56. Treatment of patients with hepatitis C virus (HCV) genotype 3 infection in the era of direct acting antivirals (DAA): Data from the German Hepatitis C-Registry (DHC-R)  
    Markus Cornberg, Peter Buggisch,… Ralph Link,…et al.  
    The Internalional Liver Congress / EASL 2016

  57. Outcomes and costs of treating hepatitis C patients in the era of first generation protease inhibitors-Results from the PAN study.
    J.T. Stahmeyer, S. Rossol, ……R. Link, Ch. Krauth et al.

     

Stand:  01.04.2016    
gez. Dr. Ralph Link

Seitenaktionen